113 related articles for article (PubMed ID: 35964648)
1. EXPRESSION OF OSTEOPONTIN AND OSTEONECTIN IN BREAST AND PROSTATE CANCER CELLS WITH DIFFERENT SENSITIVITY TO DOXORUBICIN.
Zadvornyi T; Lukianova N; Borikun T; Gogol S; Virych P; Lykhova O; Chekhun V
Exp Oncol; 2022 Aug; 44(2):107-112. PubMed ID: 35964648
[TBL] [Abstract][Full Text] [Related]
2. EXPRESSION OF MARKERS OF BONE TISSUE REMODELING IN BREAST CANCER AND PROSTATE CANCER CELLS IN VITRO.
Lukianova N; Zadvornyi T; Kashuba E; Borikun T; Mushii О; Chekhun V
Exp Oncol; 2022 May; 44(1):39-46. PubMed ID: 35548963
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
Yang L; Wei L; Zhao W; Wang X; Zheng G; Zheng M; Song X; Zuo W
Mol Med Rep; 2012 Feb; 5(2):373-6. PubMed ID: 22143930
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer.
Schneider S; Yochim J; Brabender J; Uchida K; Danenberg KD; Metzger R; Schneider PM; Salonga D; Hölscher AH; Danenberg PV
Clin Cancer Res; 2004 Mar; 10(5):1588-96. PubMed ID: 15014008
[TBL] [Abstract][Full Text] [Related]
5. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
Takeuchi S; Seike M; Noro R; Soeno C; Sugano T; Zou F; Uesaka H; Nishijima N; Matsumoto M; Minegishi Y; Kubota K; Gemma A
Int J Oncol; 2014 Jun; 44(6):1886-94. PubMed ID: 24714722
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in matricellular SPP1 and SPARC contribute to susceptibility to papillary thyroid cancer.
Su X; Xu BH; Zhou DL; Ye ZL; He HC; Yang XH; Zhang X; Liu Q; Ma JJ; Shao Q; Yang AK; He CY
Genomics; 2020 Nov; 112(6):4959-4967. PubMed ID: 32919020
[TBL] [Abstract][Full Text] [Related]
8. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
9. SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility.
Chen LZ; He CY; Su X; Peng JL; Chen DL; Ye Z; Yang DD; Wang ZX; Wang F; Shao JY; Xu RH
Gene; 2018 Jan; 640():43-50. PubMed ID: 28962925
[TBL] [Abstract][Full Text] [Related]
10. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.
Hahnel A; Wichmann H; Kappler M; Kotzsch M; Vordermark D; Taubert H; Bache M
Radiat Oncol; 2010 Sep; 5():82. PubMed ID: 20849637
[TBL] [Abstract][Full Text] [Related]
11. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
12. Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells.
Watkins G; Martin TA; Bryce R; Mansel RE; Jiang WG
Prostaglandins Leukot Essent Fatty Acids; 2005 Apr; 72(4):273-8. PubMed ID: 15763439
[TBL] [Abstract][Full Text] [Related]
13. Osteonectin (SPARC) prognostic value in prostate cancer.
Chekhun V; Borikun T; Zadvornyi T; Mushii O; Stakhovsky E; Vitruk Y; Lukianova N
Pathol Res Pract; 2024 Feb; 254():155053. PubMed ID: 38199134
[TBL] [Abstract][Full Text] [Related]
14. Methylation-mediated expression of SPARC is correlated with tumor progression and poor prognosis of breast cancer.
Li XL; Li JL; Qiu DJ; Ma L
Neoplasma; 2022 Jul; 69(4):794-806. PubMed ID: 35400166
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs.
Yalovenko TM; Todor IM; Lukianova NY; Chekhun VF
Exp Oncol; 2016 Jun; 38(2):84-8. PubMed ID: 27356575
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway.
Zhang H; Guo M; Chen JH; Wang Z; Du XF; Liu PX; Li WH
Cell Physiol Biochem; 2014; 33(4):991-1002. PubMed ID: 24714122
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.
Mallappa S; Neeli PK; Karnewar S; Kotamraju S
Mol Carcinog; 2019 Jul; 58(7):1118-1133. PubMed ID: 30834613
[TBL] [Abstract][Full Text] [Related]
19. Acetaminophen attenuates doxorubicin-induced cardiac fibrosis via osteopontin and GATA4 regulation: reduction of oxidant levels.
Schunke KJ; Coyle L; Merrill GF; Denhardt DT
J Cell Physiol; 2013 Oct; 228(10):2006-14. PubMed ID: 23526585
[TBL] [Abstract][Full Text] [Related]
20. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ
Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
